CRE 16336

Drug Profile

CRE 16336

Alternative Names: EML 16336

Latest Information Update: 11 Jun 2003

Price : $50

At a glance

  • Originator Merck KGaA; Ono Pharmaceutical
  • Developer Merck KGaA
  • Class
  • Mechanism of Action Glucose stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Insulin resistance; Type 2 diabetes mellitus

Most Recent Events

  • 11 Jun 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (PO)
  • 11 Jun 2003 Discontinued - Phase-II for Insulin resistance in Europe (unspecified route)
  • 21 May 2003 Suspended - Phase-II for Type-2 diabetes mellitus in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top